Amvuttra® (vutrisiran) significantly reduces mortality and a range of important cardiovascular events in patients with attr amyloidosis with cardiomyopathy: additional data from helios-b

Cambridge, mass.--(business wire)--alnylam pharmaceuticals, inc. (nasdaq: alny), the leading rnai therapeutics company, today presented the most contemporary analysis of the helios-b phase 3 study of vutrisiran for the treatment of attr amyloidosis with cardiomyopathy (attr-cm) as a late-breaking abstract at the heart failure 2025 congress, a scientific congress of the european society of cardiology, taking place may 17-20 in belgrade, serbia. the results demonstrate that vutrisiran, which rapi.
ALNY Ratings Summary
ALNY Quant Ranking